A medical research cannabis company has obtained a critical approval for its investigation of a drug to treat uncontrolled pain in advanced cancer patients.

On Monday (November 25), Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) informed its shareholders the US Food and Drug Administration (FDA) approved the reopening of a clinical trial for PPP001, also known as Qixleef, for pain management in patients with cancer.


In an exclusive interview with the Investing News Network (INN), Guy Chamberland, CEO and chief regulatory officer of Tetra, explained how the drug went from having no chance of ever being commercialized to getting revived by the US regulator.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

However, now Tetra will be able to resume the trial and begin enrollment of patients “as quickly as possible.” According to the Canadian company, the federal agency approved the restart of the trial after reviewing the files of the trial and guaranteeing the safety standards for participating patients.

Chamberland told INN the company was faced with resetting its trial due to the mycotoxins in its original model.

In response to this conflict, the company developed a synthetic version for its drug. However, Chamberland said the nature of a wide variety of patients is to consume the drug by way of dried flower.

Chamberland said Tetra submitted to the US regulator a month ago almost as an afterthought since the Canadian regulators told the company they were not interested in any drug with mycotoxins. “Our hopes were actually pretty low,” he said.

That changed when the US regulator asked for a meeting, at which the company expected to hear a simple response.

“To our surprise, it was beyond that, they were basically ready to approve it.

“Their biggest concern was not the mycotoxins; they obviously thought we were addressing it adequately for them. The issue was patient safety from a liver toxicity point of view,” he told INN.

The regulator raised questions on the monitoring of suicidal tendencies among its studied patients and patients with liver toxicity issues.

Shares of the company jumped following the announcement. Tetra Bio-Pharma opened at a price of C$0.22. As of market close on Monday’s trading session, the company finished with a share price uptick of 25 percent, up to C$0.25.

The trial, dubbed Plenitude, consists of a four-week double-blind, randomized, placebo-controlled, parallel group design study by the company. There are 78 adult patients taking part in it.

Tetra is moving ahead of the results from its trial by setting in place the potential commercialization of Qixleef through a search for a commercial partner to aid in the distribution and sale of its medicine.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The company is also bullish on the development of its Caumz drug, a cannabinoid medicine for chronic pain using 9.5 percent synthetic tetrahydrocannabinol (THC) and 2.5 percent cannabidiol (CBD).

Tetra is expecting approval of Caumz in the US and Canada by late 2020.

The spotlight for marijuana-based medicines expanded after GW Pharmaceuticals (NASDAQ:GWPH) obtained approval from the FDA for its medicine Epidiolex, a drug designed to treat seizures related to Lennox-Gastaut syndrome and Dravet syndrome in patients aged two years and older.

The landmark approval for the CBD drug marked a shift in potential for the pharmaceutical space based on marijuana assets.

A pharmaceutical approach to cannabis has been promised by a variety of public firms in the hopes the differentiator will offer better results than the more direct grower play in the industry.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less

ADASTRA HOLDINGS LTD. ENGAGES HYBRID FINANCIAL LTD.

Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (FRA: D2EP) (“Adastra”, or the “Company”) is pleased to announce that it has retained Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for Adastra and to broaden the Company’s reach within the investment community.

Keep reading... Show less